Clinical Trial

Treating Claudin18.2-positive Advanced Solid Tumors with XKDCT225(Targeting Claudin18.2-CAR-T)

Name: Treating Claudin18.2-positive Advanced Solid Tumors with XKDCT225(Targeting Claudin18.2-CAR-T) — clinical trial record (NCT06782425)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

A single-center, single-arm, dose-escalation exploratory clinical trial of the safety, efficacy, and pharmacokinetics of XKDCT225 cell injection in Claudin18.2-positive advanced solid tumors

Trial Details

NCT Number	NCT06782425
Lead Sponsor	Shenzhen Celconta Life Science Co., Ltd.
Conditions	Claudin18.2 Positive Advanced Solid Tumors
Enrollment	18 participants
Start Date	2025-01
Primary Completion	2028-01 (estimated)
Study Completion	2028-01 (estimated)
Updated on ClinicalTrials.gov	2025-01-17